Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

URL of this page:

Phosphate Salts

What is it?

Phosphorus is an essential mineral found in many foods. In the diet and body, phosphorus usually binds to other minerals in the form of phosphate salts.

Phosphates are involved in cell structure, energy transport and storage, vitamin function, and many other essential processes in the body. Phosphate salts can act as laxatives by causing more fluid to be drawn into the intestines and making the gut push out its contents faster.

People use phosphate salts for bowel cleansing, low blood levels of phosphate, constipation, high blood levels of calcium, and heartburn. They are also used for athletic performance, osteoporosis, and many other conditions, but there is no good scientific evidence to support these other uses.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for PHOSPHATE SALTS are as follows:

Effective for...

  • Emptying the colon before a colonoscopy. Taking sodium phosphate products by mouth before a colonoscopy is effective for bowel cleansing. Some sodium phosphate products are approved by the US FDA for this use. But taking sodium phosphate can increase the risk of kidney damage in some people and should be used with caution.
  • Low levels of phosphate in the blood (hypophosphatemia). Taking sodium or potassium phosphate by mouth or by IV is effective for preventing or treating low phosphate levels in the blood. IV products can only be given by a healthcare provider.

Likely effective for...

  • Constipation. Sodium phosphate is an FDA-approved over-the-counter (OTC) ingredient for treating constipation. OTC products are taken by mouth or used as enemas.
  • Indigestion (dyspepsia). Aluminum phosphate and calcium phosphate are FDA-approved ingredients in OTC antacids.
  • High levels of calcium in the blood (hypercalcemia). Taking phosphate salts by mouth is likely effective for treating high levels of calcium in the blood. But calcium phosphate should not be used since it contains calcium and can increase calcium levels.

Possibly effective for...

  • Kidney stones. Taking potassium phosphate by mouth can help prevent calcium kidney stones from forming in people with high urine levels of calcium.
There is interest in using phosphate salts for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

Is it safe?

When taken by mouth: Phosphate salts are likely safe when consumed in the diet, or when supplements are used appropriately for a short time. Phosphate salts might cause side effects such as stomach upset, diarrhea, headache, and others.

Phosphate salts (as phosphorous) are possibly unsafe when taken in doses higher than 4 grams daily for adults 70 years and younger, or in doses higher than 3 grams daily for people over 70 years. Regular long-term use can upset the balance of phosphates and other chemicals in the body and should be monitored by a healthcare professional to avoid serious side effects.

When given as an enema (rectally): Phosphate salts are likely safe for most people when inserted into the rectum appropriately and short-term. But these products shouldn't be used more than once daily.

Special precautions & warnings:

Pregnancy and breast-feeding: Phosphate salts are commonly consumed in the diet. Phosphate salts are possibly unsafe when taken in amounts above the tolerable upper intake level (UL). The UL is 3.5 grams daily during pregnancy and 4 grams daily while breast-feeding.

Children: Phosphate salts are commonly consumed in the diet. Phosphate salts are possibly unsafe when taken in amounts that exceed the tolerable upper intake level (UL). The UL is 3 grams daily for children 1-8 years old and 4 grams daily for children 9 years and older.

Giving a sodium phosphate enema to children OVER 2 years of age is likely safe when no more than one dose is given every 24 hours. But it is likely unsafe to give more than one dose every 24 hours, or to give a sodium phosphate enema to children who are under 2 years of age.

Gastrointestinal (GI) conditions:: Sodium phosphate can cause damage to the intestines in some people. If you have an obstruction or have an inflammatory GI condition, avoid using sodium phosphate.

High levels of calcium in the blood (hypercalcemia):: Use phosphate salts cautiously if you have hypercalcemia. Too much phosphate could cause calcium to be deposited where it shouldn't be in your body.

High levels of phosphate in the blood: People with Addison's disease, severe heart and lung disease, kidney disease, thyroid problems, or liver disease are more likely to have too much phosphate in their blood when they take phosphate salts. Use phosphate salts only while under the care of a healthcare professional if you have one of these conditions.

Kidney disease: Use phosphate salts only while under the care of a healthcare professional if you have kidney problems.

Are there interactions with medications?

Do not take this combination.
Erdafitinib (Balversa)
Erdafitinib increases the amount of phosphate in the blood. Taking phosphate salts along with erdafitinib can cause very high phosphate levels and serious side effects. Avoid phosphates when using erdafitinib.
Be cautious with this combination.
Bisphosphonate medications and phosphate salts can both lower calcium levels in the body. Taking large amounts of phosphate salts along with bisphosphonate medications might cause calcium levels to become too low.

Are there interactions with herbs and supplements?

Phosphate can bind with calcium. This reduces the body's ability to absorb phosphate and calcium. To avoid this interaction, phosphate should be taken at least 2 hours before or after taking calcium.
Phosphate can bind with iron. This reduces the body's ability to absorb phosphate and iron. To avoid this interaction, phosphate should be taken at least 2 hours before or after taking iron.
Phosphate can bind with magnesium. This reduces the body's ability to absorb phosphate and magnesium. To avoid this interaction, phosphate should be taken at least 2 hours before or after taking magnesium.

Are there interactions with foods?

Taking phosphate with phosphate-containing foods and drinks might increase phosphate levels and increase the risk of side effects, especially in people with kidney problems. Phosphate-containing foods and beverages include cola, wine, beer, whole grain cereals, nuts, dairy products, and some meats.

How is it typically used?

Phosphate (as phosphorus) is found in many foods, including meat, fish, eggs, and dairy products. Phosphate deficiencies are rare. The amount that should be consumed on a daily basis is called the recommended dietary allowance (RDA). For adults, the RDA is 700 mg. While pregnant or breast-feeding, the RDA is 1250 mg for those 14-18 years of age and 700 mg for those over 18 years of age. In children, the RDA depends on age. Speak with a healthcare provider to find out what type of product and dose might be best for a specific condition.

Other names

Aluminum phosphate, Bone Phosphate, Calcium phosphate, Calcium Orthophosphate, Calcium Phosphate Dibasic Anhydrous, Calcium Phosphate-Bone Ash, Calcium Phosphate Dibasic Dihydrate, Calcium Phosphate Dibasique Anhydre, Calcium Phosphate Dibasique Dihydrate, Calcium Phosphate Tribasic, Calcium Phosphate Tribasique, Dibasic Calcium Phosphate Dihydrate, Di-Calcium Phosphate, Dicalcium Phosphate, Dicalcium Phosphates, Neutral Calcium Phosphate, Orthophosphate de Calcium, Phosphate d'Aluminium, Phosphate de Calcium, Phosphate de Magnésium, Phosphate Neutre de Calcium, Phosphate d'Os, Phosphate Tricalcium, Precipitated Calcium Phosphate, Précipitation du Phosphate de Calcium, Précipité de Phosphate de Calcium, Tertiary Calcium Phosphate, Tricalcium Phosphate, Whitlockite, Magnesium Phosphate, Merisier, Potassium phosphate, Dibasic Potassium Phosphate, Dipotassium Hydrogen Orthophosphate, Dipotassium Monophosphate, Dipotassium Phosphate, Monobasic Potassium Phosphate, Potassium Acid Phosphate, Potassium Biphosphate, Potassium Dihydrogen Orthophosphate, Potassium Hydrogen Phosphate, Phosphate de Dipotassium, Phosphate d'Hydrogène de Potassium, Phosphate de Potassium, Phosphate de Potassium Dibasique, Phosphate de Potassium Monobasique, Sodium phosphate, Anhydrous Sodium Phosphate, Dibasic Sodium Phosphate, Disodium Hydrogen Orthophosphate, Disodium Hydrogen Orthophosphate Dodecahydrate, Disodium Hydrogen Phosphate, Disodium Phosphate, Phosphate of Soda, Sales de Fosfato, Sels de Phosphate, Sodium Orthophosphate, Orthophosphate Disodique d'Hydrogène, Phosphate Disodique d'Hydrogène, Orthophosphate de Sodium, Phosphate de Sodium Anhydre, Phosphate de Sodium Dibasique, Phosphorus.


To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.


  1. Rastogi A, Bhatt N, Rossetti S, Beto J. Management of hyperphosphatemia in end-stage renal disease: A New Paradigm. J Ren Nutr. 2021;31:21-34. View abstract.
  2. Hung SY, Chen HC, Ke TW, et al. Noninferiority clinical trial comparing the bowel cleansing efficacy of sodium phosphate tablets (Quiklean(®)) with a polyethylene glycol/bisacodyl kit. World J Gastroenterol 2021;27:428-441. View abstract.
  3. Ploszczyca K, Gajda R, Czuba M. The effects of sodium phosphate supplementation on the cardiorespiratory system and gross efficiency during exercise under hypoxia in male cyclists: A randomized, placebo-controlled, cross-over study. Nutrients 2021;13:3556. View abstract.
  4. Dang JT, Moolla M, Dang TT, et al. Sodium phosphate is superior to polyethylene glycol in constipated patients undergoing colonoscopy: a systematic review and meta-analysis. Surg Endosc. 2020. View abstract.
  5. FDA Drug Safety Communication: FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation. FDA Drug Safety and Availability. Available at: [Accessed: February 26, 2021.]
  6. Prescribing information: BALVERSA (erdafitinib) tablets. U.S. Food and Drug Administration. [Accessed: February 26, 2021.]
  7. Visicol Tablets Prescribing information. Salix Pharmaceuticals, Raleigh, NC. March 2013. ( Accessed 09/28/17.
  8. Delegge M, Kaplan R. Efficacy of bowel preparation with the use of a prepackaged, low fibre diet with a low sodium, magnesium citrate cathartic vs. a clear liquiddiet with a standard sodium phosphate cathartic. Aliment Pharmacol Ther. 2005 Jun 15;21:1491-5. View abstract.
  9. Johnson DA, Barkun AN, Cohen LB, et al.; US Multi-Society Task Force on Colorectal Cancer. Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2014;109:1528-45. View abstract.
  10. Nam SY, Choi IJ, Park KW, Ryu KH, Kim BC, Sohn DK, Nam BH, Kim CG. Risk of hemorrhagic gastropathy associated with colonoscopy bowel preparation using oral sodium phosphate solution. Endoscopy. 2010 Feb;42:109-13. View abstract.
  11. Ori Y, Rozen-Zvi B, Chagnac A, Herman M, Zingerman B, Atar E, Gafter U, Korzets A. Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience. Arch Intern Med. 2012 Feb 13;172:263-5. View abstract.
  12. Ladenhauf HN, Stundner O, Spreitzhofer F, Deluggi S. Severe hyperphosphatemia after administration of sodium-phosphate containing laxatives in children: case series and systematic review of literature. Pediatr Surg Int. 2012 Aug;28:805-14. View abstract.
  13. Schaefer M, Littrell E, Khan A, Patterson ME. Estimated GFR Decline Following Sodium Phosphate Enemas Versus Polyethylene Glycol for Screening Colonoscopy: A Retrospective Cohort Study. Am J Kidney Dis. 2016 Apr;67:609-16. View abstract.
  14. Brunelli SM. Association between oral sodium phosphate bowel preparations and kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 Mar;53:448-56. View abstract.
  15. Choi NK, Lee J, Chang Y, Kim YJ, Kim JY, Song HJ, Shin JY, Jung SY, Choi Y, Lee JH, Park BJ. Acute renal failure following oral sodium phosphate bowel preparation: a nationwide case-crossover study. Endoscopy. 2014 Jun;46:465-70. View abstract.
  16. Juluri R, Eckert G, Imperiale TF. Polyethylene glycol vs. sodium phosphate for bowel preparation: a treatment arm meta-analysis of randomized controlled trials. BMC Gastroenterol. 2011 Apr 14;11:38. View abstract.
  17. Belsey J, Crosta C, Epstein O, Fischbach W, Layer P, Parente F, Halphen M. Meta-analysis: the relative efficacy of oral bowel preparations for colonoscopy 1985-2010. Aliment Pharmacol Ther. 2012 Jan;35:222-37. View abstract.
  18. Belsey J, Crosta C, Epstein O, Fischbach W, Layer P, Parente F, Halphen M. Meta-analysis: efficacy of small bowel preparation for small bowel video capsule endoscopy. Curr Med Res Opin. 2012 Dec;28:1883-90. View abstract.
  19. Czuba M, Zajac A, Poprzecki S, Cholewa J, Woska S. Effects of Sodium Phosphate Loading on Aerobic Power and Capacity in off Road Cyclists. J Sports Sci Med. 2009 Dec 1;8:591-9. View abstract.
  20. Brewer CP, Dawson B, Wallman KE, Guelfi KJ. Effect of repeated sodium phosphate loading on cycling time-trial performance and VO2peak. Int J Sport Nutr Exerc Metab. 2013 Apr;23:187-94. View abstract.
  21. Buck CL, Wallman KE, Dawson B, Guelfi KJ. Sodium phosphate as an ergogenic aid. Sports Med. 2013 Jun;43:425-35. View abstract.
  22. Buck CL, Dawson B, Guelfi KJ, McNaughton L, Wallman KE. Sodium phosphate supplementation and time trial performance in female cyclists. J Sports Sci Med. 2014 Sep 1;13:469-75. View abstract.
  23. Brewer CP, Dawson B, Wallman KE, Guelfi KJ. Effect of Sodium Phosphate Supplementation on Cycling Time Trial Performance and VO2 1 and 8 Days Post Loading. J Sports Sci Med. 2014 Sep 1;13:529-34. View abstract.
  24. West JS, Ayton T, Wallman KE, Guelfi KJ. The effect of 6 days of sodium phosphate supplementation on appetite, energy intake, and aerobic capacity in trained men and women. Int J Sport Nutr Exerc Metab. 2012 Dec;22:422-9. View abstract.
  25. van Vugt van Pinxteren MW, van Kouwen MC, van Oijen MG, van Achterberg T, Nagengast FM. A prospective study of bowel preparation for colonoscopy with polyethylene glycol-electrolyte solution versus sodium phosphate in Lynch syndrome: a randomized trial. Fam Cancer. 2012 Sep;11:337-41. View abstract.
  26. Manukyan MN, Tolan K, Severge U, Attaallah W, Kebudi A, Cingi A. Prospective randomized comparison of oral sodium phosphate and sennoside A+B calcium lavage for colonoscopy preparation. Surg Laparosc Endosc Percutan Tech. 2011 Apr;21:90-3. View abstract.
  27. Lee SH, Lee DJ, Kim KM, Seo SW, Kang JK, Lee EH, Lee DR. Comparison of the efficacy and safety of sodium phosphate tablets and polyethylene glycol solution for bowel cleansing in healthy Korean adults. Yonsei Med J. 2014 Nov;55:1542-55. View abstract.
  28. Kopec BJ, Dawson BT, Buck C, Wallman KE. Effects of sodium phosphate and caffeine ingestion on repeated-sprint ability in male athletes. J Sci Med Sport. 2016 Mar;19:272-6. View abstract.
  29. Jung YS, Lee CK, Kim HJ, Eun CS, Han DS, Park DI. Randomized controlled trial of sodium phosphate tablets vs polyethylene glycol solution for colonoscopy bowel cleansing. World J Gastroenterol. 2014 Nov 14;20:15845-51. View abstract.
  30. Heaney RP, Recker RR, Watson P, Lappe JM. Phosphate and carbonate salts of calcium support robust bone building in osteoporosis. Am J Clin Nutr. 2010 Jul;92:101-5. View abstract.
  31. Ell C, Fischbach W, Layer P, Halphen M. Randomized, controlled trial of 2 L polyethylene glycol plus ascorbate components versus sodium phosphate for bowel cleansing prior to colonoscopy for cancer screening. Curr Med Res Opin. 2014 Dec;30:2493-503. View abstract.
  32. Buck CL, Henry T, Guelfi K, Dawson B, McNaughton LR, Wallman K. Effects of sodium phosphate and beetroot juice supplementation on repeated-sprint ability in females. Eur J Appl Physiol. 2015 Oct;115:2205-13. View abstract.
  33. Buck C, Guelfi K, Dawson B, McNaughton L, Wallman K. Effects of sodium phosphate and caffeine loading on repeated-sprint ability. J Sports Sci. 2015;33:1971-9. View abstract.
  34. Brewer CP, Dawson B, Wallman KE, Guelfi KJ. Effect of sodium phosphate supplementation on repeated high-intensity cycling efforts. J Sports Sci. 2015;33:1109-16. View abstract.
  35. Folland, JP, Stern, R, and Brickley, G. Sodium phosphate loading improves laboratory cycling time-trial performance in trained cyclists. J Sci Med Sport 2008;11:464-8. View abstract.
  36. Fisher, JN and Kitabchi, AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 1983;57:177-80. View abstract.
  37. Terlevich A, Hearing SD, Woltersdorf WW, et al. Refeeding syndrome: effective and safe treatment with Phosphates Polyfusor. Aliment Pharmacol Ther 2003;17:1325-9. View abstract.
  38. Savica, V, Calo, LA, Monardo, P, et al. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia. J Ren Nutr 2009;19:69-72. View abstract.
  39. Hu, S, Shearer, GC, Steffes, MW, Harris, WS, and Bostom, AG. Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia. Am J Kidney Dis 2011;57:181-2. View abstract.
  40. Schaiff, RA, Hall, TG, and Bar, RS. Medical treatment of hypercalcemia. Clin Pharm 1989;8:108-21. View abstract.
  41. Elliott, GT and McKenzie, MW. Treatment of hypercalcemia. Drug Intell Clin Pharm 1983;17:12-22. View abstract.
  42. Bugg, NC and Jones, JA. Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit. Anaesthesia 1998;53:895-902. View abstract.
  43. OsmoPrep Prescribing information. Salix Pharmaceuticals, Raleigh, NC. October 2012. (, accessed 02/24/15).
  44. FDA OTC ingredients list, April 2010. Available at: (accessed 2/7/15).
  45. Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 1998;280:1067-73. View abstract.
  46. Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone (1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003;88:4214-20. View abstract.
  47. Lindsay R, Nieves J, Formica C, et al. Randomized controlled study of the effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5. View abstract.
  48. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 1996;276:631-6. View abstract.
  49. Leung AC, Henderson IS, Halls DJ, Dobbie JW. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed) 1983;286:1379-81. View abstract.
  50. Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis 1989;13:194-9. View abstract.
  51. Hergesell O, Ritz E. Phosphate binders on iron basis: a new perspective? Kidney Intl Suppl 1999;73:S42-5. View abstract.
  52. Peters T, Apt L, Ross JF. Effect of phosphates upon iron absorption studied in normal human subjects and in an experimental model using dialysis. Gastroenterology 1971;61:315-22. View abstract.
  53. Monsen ER, Cook JD. Food iron absorption in human subjects IV. The effects of calcium and phosphate salts on the absorption of nonheme iron. Am J Clin Nutr 1976;29:1142-8. View abstract.
  54. Lindsay R, Nieves J, Henneman E, et al. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993;77:1535-9. View abstract.
  55. Campisi P, Badhwar V, Morin S, Trudel JL. Postoperative hypocalcemic tetany caused by Fleet Phospho-Soda preparation in a patient taking alendronate sodium. Dis Colon Rectum 1999;42:1499-501. View abstract.
  56. Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf 2003;26:1093-115. View abstract.
  57. Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. New Engl J Med 1989;320:1110-3. View abstract.
  58. Saadeh G, Bauer T, Licata A, Sheeler L. Antacid-induced osteomalacia. Cleve Clin J Med 1987;54:214-6. View abstract.
  59. Gregory JF. Case study: folate bioavailability. J Nutr 2001;131:1376S-1382S. View abstract.
  60. Insogna KL, Bordley DR, Caro JF, Lockwood DH. Osteomalacia and weakness from excessive antacid ingestion. JAMA 1980;244:2544-6. View abstract.
  61. Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr 2002;21:239-44.. View abstract.
  62. Rosen GH, Boullata JI, O'Rangers EA, et al. Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia. Crit Care Med 1995;23:1204-10. View abstract.
  63. Perreault MM, Ostrop NJ, Tierney MG. Efficacy and safety of intravenous phosphate replacement in critically ill patients. Ann Pharmacother 1997;31:683-8. View abstract.
  64. Duffy DJ, Conlee RK. Effects of phosphate loading on leg power and high intensity treadmill exercise. Med Sci Sports Exerc 1986;18:674-7. View abstract.
  65. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press, 1999. Available at:
  66. Carey CF, Lee HH, Woeltje KF (eds). Washington Manual of Medical Therapeutics. 29th ed. New York, NY: Lippincott-Raven, 1998.
  67. Alvarez-Arroyo MV, Traba ML, Rapado TA, et al. Correlation between 1.25 dihydroxyvitamin D serum levels and fractional rate of intestinal calcium absorption in hypercalciuric nephrolithiasis. Role of phosphate. Urol Res 1992;20:96-7. View abstract.
  68. Heaton KW, Lever JV, Barnard RE. Osteomalacia associated with cholestyramine therapy for post-ileectomy diarrhea. Gastroenterology 1972;62:642-6. View abstract.
  69. Becker GL. The case against mineral oil. Am J Digestive Dis 1952;19:344-8. View abstract.
  70. Schwarz KB, Goldstein PD, Witztum JL, et al. Fat-soluble vitamin concentrations in hypercholestrolemic children treated with colestipol. Pediatrics 1980;65:243-50. View abstract.
  71. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975;16:93-8. View abstract.
  72. Spencer H, Menaham L. Adverse effects of aluminum-containing antacids on mineral metabolism. Gastroenterology 1979;76:603-6. View abstract.
  73. Roberts DH, Knox FG. Renal phosphate handling and calcium nephrolithiasis: role of dietary phosphate and phosphate leak. Semin Nephrol 1990;10:24-30. View abstract.
  74. Harmelin DL, Martin FR, Wark JD. Antacid-induced phosphate depletion syndrome presenting as nephrolithiasis. Aust NZ J Med 1990;20:803-5. View abstract.
  75. Yates AA, Schlicker SA, Suitor CW. Dietary reference intakes: The new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699-706. View abstract.
  76. Fauci AS, Braunwald E, Isselbacher KJ, et al. Harrison's Principles of Internal Medicine, 14th ed. New York, NY: McGraw-Hill, 1998.
  77. Shils ME, Olson JA, Shike M, Ross AC, eds. Modern Nutrition in Health and Disease. 9th ed. Baltimore, MD: Williams & Wilkins, 1999.
  78. Galloway SD, Tremblay MS, Sexsmith JR, Roberts CJ. The effects of acute phosphate supplementation in subjects of different aerobic fitness levels. Eur J Appl Physiol Occup Physiol 1996;72:224-30. View abstract.
  79. Helikson MA, Parham WA, Tobias JD. Hypocalcemia and hyperphosphatemia after phosphate enema use in a child. J Pediatr Surg 1997;32:1244-6. View abstract.
  80. DiPalma JA, Buckley SE, Warner BA, et al. Biochemical effects of oral sodium phosphate. Dig Dis Sci 1996;41:749-53. View abstract.
  81. Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997;29:103-5. View abstract.
  82. Clarkston WK, Tsen TN, Dies DF, et al. Oral sodium phosphate versus sulfate-free polyethylene glycol electrolyte lavage solution in outpatient preparation for colonoscopy: a prospective comparison. Gastrointest Endosc 1996;43:42-8. View abstract.
  83. Hill AG, Teo W, Still A, et al. Cellular potassium depletion predisposes to hypokalaemia after oral sodium phosphate. Aust N Z J Surg 1998;68:856-8. View abstract.
  84. Heller HJ, Reza-Albarran AA, Breslau NA, Pak CY. Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria. J Urol 1998;159:1451-5; discussion 1455-6. View abstract.
  85. Breslau NA, Heller HJ, Reza-Albarran AA, Pak CY. Physiological effects of slow release potassium phosphate for absorptive hypercalciuria: a randomized double-blind trial. J Urol 1998;160:664-8. View abstract.
  86. Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
  87. Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.
  88. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  89. Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
Last reviewed - 02/15/2022